Iadademstat and gilteritinib synergistically abrogate viability of both treatment-naïve and drug-resistant AML cells. (October 2022) - Sacilotto, N.; Strzemieczna, E.M.; Purcet, S.; Mascaró, C.; Soliva, R.; Xaus, J.